Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-1RA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-1RA (IL1RN) Recombinant Protein (Wild-Type & Engineered Variants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View IL1RN Products |
| Gene Delivery | IL1RN Promise-ORF / Lentivirus Full-length ORF for stable cell lines and secretion studies. |
View IL1RN Products |
| Benchmark Ab | Anti-IL-1RA Detection Antibody (Research Grade) For PK/PD and bioanalytical assay development. |
View IL1RN Products |
| Validator | IL1RN siRNA Set For knockdown verification and specificity controls. |
View IL1RN Products |
| IL-1β (Ligand) | IL1B Recombinant Protein Natural ligand for competitive binding and inhibition assays. |
View IL1B Products |
| IL-1R1 (Receptor) | IL1R1 ECD-Fc Fusion Protein Soluble receptor for affinity and blocking studies. |
View IL1R1 Products |
| IL-1α (Alternate Ligand) | IL1A Recombinant Protein Alternative ligand for broad antagonist validation. |
View IL1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Receptor Binding Affinity (vs IL-1R1) | High-purity IL-1RA (>95%) with verified endotoxin levels (<1 EU/μg) for accurate SPR/BLI kinetic determination |
| Functional Inhibition (blocking IL-1β/IL-1α) | Bioactive-grade protein sequence-verified for cell-based reporter assays (e.g., IL-6 suppression in fibroblasts) |
| Species Cross-Reactivity (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with identical purity standards for preclinical bridging studies |
| High-Concentration Formulation Stability | Aggregation-tested (monomer content >95% by SEC-HPLC) for subcutaneous delivery modeling |
| Specificity Controls | Validated siRNA included for target-specific vs. off-target effect verification |
Live IL-1RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The IL-1RA therapeutic paradigm is expanding beyond rheumatoid arthritis into broader inflammatory indications. While Anakinra (recombinant IL-1RA) established the proof-of-concept, the current R&D landscape focuses on half-life extension strategies and novel delivery systems for chronic diseases. Key trends include the repositioning of IL-1RA for cardiovascular risk reduction (building on CANTOS trial insights), cytokine storm management in infectious diseases, and metabolic disorders including Type 2 diabetes. Biosimilar development for Anakinra is intensifying, while next-generation molecules explore Fc-fusion and PEGylation to overcome the native protein's short plasma half-life (4-6 hours). Localized gene therapy approaches (e.g., AAV-mediated IL1RN delivery) are also emerging for conditions like osteoarthritis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Protein (Short-acting) | Biogen (Anakinra), Biosimilar Developers | Rheumatoid Arthritis, CAPS, Gout | Endotoxin-controlled protein for safety; High-purity reference standards |
| Long-Acting IL-1RA (Fc-Fusion/PEG) | Preclinical/Clinical Phase | Cardiovascular, Diabetes, Pericarditis | Stability assays (aggregation analysis); Cyno cross-reactivity for tox studies |
| Anti-IL-1β mAbs | Novartis (Canakinumab) | Periodic Fever Syndromes | IL-1β/IL-1RA competition assays; Epitope binning |
| IL-1R1 Antagonists | Academic/Early Biotech | Inflammatory Bowel Disease | Receptor binding inhibition assays; Heterodimer disruption validation |
| Gene Therapy | Emerging Biopharma | Osteoarthritis (Local delivery) | Expression validation (need specific Abs and siRNA) |
Molecular Differentiation & Assay Strategy
As a soluble cytokine antagonist, best-in-class IL-1RA molecules differentiate through pharmacokinetic optimization, tissue penetration, and receptor selectivity, not ADCC/CDC. Key parameters include:
- Receptor Binding Affinity & Kinetics: Must compete effectively with IL-1β/IL-1α for IL-1R1 (KD ~1-10 nM). Fc-fusion variants require validation of retained binding. TarMart provides HEK293-expressed IL-1R1 ECD-Fc for SPR/BLI.
- Functional Potency: Inhibition selectivity against IL-1β vs. IL-1α matters in disease contexts. TarMart offers high-purity IL1B and IL1A proteins (endotoxin <0.1 EU/μg) for cell-based reporter assays.
- High-Concentration Stability: Subcutaneous formulations (100-150 mg/mL) risk aggregation. TarMart provides SEC-HPLC (monomer >95%), DLS (PDI <0.2), and DSC (Tm) analysis.
- Species Cross-Reactivity: Cynomolgus models are critical for tox studies. TarMart supplies Cyno IL-1RA/IL-1R1 proteins for cross-binding validation.
- Specificity Controls: IL1RN siRNA sets help confirm target-specific effects and rule out false positives from endotoxin or aggregates.
Related Target Recommendations (Cross-Selling)
- IL-1β (IL1B): Direct ligand competitor; essential for functional inhibition assays. Product link: View IL1B Products
- IL-1R1 (IL1R1): Cognate receptor; required for binding studies. Product link: View IL1R1 Products
- NLRP3: Upstream regulator of IL-1β maturation; NLRP3 inhibitors use IL-1RA/IL-1β as downstream biomarkers. Product link: View NLRP3 Products
- IL-1α (IL1A): Alternative ligand for broad antagonist validation. Product link: View IL1A Products